Antiviral strategies in hepatitis C virus infection
- PMID: 22300469
- DOI: 10.1016/S0168-8278(12)60010-5
Antiviral strategies in hepatitis C virus infection
Abstract
Resolution of the three-dimensional structures of several hepatitis C virus (HCV) proteins, together with the development of replicative cell culture systems, has led to the identification of a number of potential targets for direct-acting antiviral (DAA) agents. Numerous families of drugs that potently inhibit the HCV lifecycle in vitro have been identified, and some of these molecules have reached early to late clinical development. Two NS3/4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1, in both treatment-naïve and treatment-experienced patients. Sustained virological response rates in the range of 6675% and 5966% (2988% if the response to the first course of therapy is taken into account) have been achieved in these two patient populations, respectively, with treatment durations of 24 to 48 weeks. A number of other DAAs are at the clinical developmental stage in combination with pegylated IFN-α and ribavirin or with other DAAs in IFN-free regimens, with or without ribavirin. They include second-wave, first-generation, and second-generation NS3/4A protease inhibitors, nucleoside/nucleotide analogue inhibitors and non-nucleoside inhibitorsof HCVRNA-dependent RNA polymerase, inhibitors of nonstructural protein 5A (NS5A) and host-targeted compounds, such as cyclophilin inhibitors and silibinin. The proof of concept that IFN-free regimens may lead to HCV eradication has recently been brought. However, new drugs may be associated with troublesome side effects and drugdrug interactions, and the ideal IFN-free DAA combination remains to be found.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9. J Hepatol. 2013. PMID: 23063419
-
Treatment of chronic hepatitis C: current and future.Curr Top Microbiol Immunol. 2013;369:321-42. doi: 10.1007/978-3-642-27340-7_13. Curr Top Microbiol Immunol. 2013. PMID: 23463207 Review.
-
A new era in the treatment of chronic hepatitis C infection.Indian J Gastroenterol. 2013 Mar;32(2):71-9. doi: 10.1007/s12664-012-0254-5. Epub 2012 Sep 28. Indian J Gastroenterol. 2013. PMID: 23054947 Review.
-
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.Liver Int. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715. Liver Int. 2015. PMID: 25529082 Review.
-
Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Ann Pharmacother. 2011. PMID: 21828346 Review.
Cited by
-
Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment.Biomedicines. 2023 May 31;11(6):1598. doi: 10.3390/biomedicines11061598. Biomedicines. 2023. PMID: 37371693 Free PMC article. Review.
-
Viral proteases as therapeutic targets.Mol Aspects Med. 2022 Dec;88:101159. doi: 10.1016/j.mam.2022.101159. Epub 2022 Nov 29. Mol Aspects Med. 2022. PMID: 36459838 Free PMC article. Review.
-
The Lived Experience of Patients Utilizing Second-Generation Direct-Acting Antiviral for Treatment of Chronic Hepatitis C Virus Infection: A Phenomenological Analysis.Int J Environ Res Public Health. 2022 Oct 1;19(19):12540. doi: 10.3390/ijerph191912540. Int J Environ Res Public Health. 2022. PMID: 36231842 Free PMC article.
-
Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach.PLoS One. 2022 Aug 30;17(8):e0272582. doi: 10.1371/journal.pone.0272582. eCollection 2022. PLoS One. 2022. PMID: 36040967 Free PMC article.
-
Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data.Healthcare (Basel). 2022 Jul 27;10(8):1400. doi: 10.3390/healthcare10081400. Healthcare (Basel). 2022. PMID: 36011057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources